Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04292262
Other study ID # FMASU M S 289/2020
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 1, 2020
Est. completion date August 30, 2020

Study information

Verified date October 2020
Source Ain Shams University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Acute Kidney Injury (AKI) is a common complication of severe trauma patients and is associated with increased morbidity and mortality.Trauma patients have many risk factors for AKI such as hypovolemic shock, rhabdomyolysis, massive transfusion, major surgeries and abdominal compartment syndrome.The primary outcome of the study is to correlate between the AKI by using RIFLE criteria and the trauma severity by using ISS .The secondary outcomes are ;the length of ICU and hospital stay and 28 days mortality in AKI patients.


Description:

• Study Population: 60 cases of polytrauma patients who have ISS>15. - Inclusion Criteria: - Age from 18 to 70 years old males or females - Injury Sensitivity Score (ISS >15 ) - Exclusion Criteria: Patients have end stage liver disease, end stage kidney disease, disseminated malignancy or decompensated heart failure. Sample size :the calculated sample size is 60 cases of trauma patients. • All patients' data will be recorded on admission and daily for 7 days: - Vital signs (blood pressure, heart rate, respiratory rate, body temperature). - Lab investigations: complete blood count, international normalized ratio, prothrombin time, arterial blood gases, kidney function tests, liver function tests, creatine kinase, creatine kinase-muscle band, creatinine clearance, serum sodium, serum potassium and serum phosphorus will be requested for all patients at admission then daily follow up by creatine kinase, creatine kinase-muscle band, kidney function tests, serum sodium, serum potassium and serum phosphorus for 7 days. Glasgow Coma Scale (GCS), Injury Severity Score (ISS),Urine output (ml/kg/h),RIFLE criteria.,Length of ICU and hospital stay,28 days mortality.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date August 30, 2020
Est. primary completion date August 30, 2020
Accepts healthy volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - • Age from 18 to 70 years old males or females - Injury Sensitivity Score (ISS >15 ) Exclusion Criteria: - Patients have end stage liver disease, end stage kidney disease, disseminated malignancy or decompensated heart failure.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Observational
Observational

Locations

Country Name City State
Egypt Hanaa El Gendy Cairo Ain Shams University Specialized Hospital

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlate between the AKI by using RIFLE criteria and the trauma severity by using ISS 7 days
Secondary the length of ICU and hospital stay and 28 days mortality in AKI patients. 28 days
See also
  Status Clinical Trial Phase
Recruiting NCT04279457 - Single-Center Prospective Study to Investigate the Difference in the Incidence of Contrast-Induced Nephropathy in High-Risk Patients With the Use of the Dye-Vert Plus System Phase 4